Blandine heads the NGS-based, cancer diagnostics product and service strategy across the continuum of biopharma partnerships, CLIA-based tests and distributed kits. She brings two decades of experience as an executive in Life Science and Consumer Packaged Goods (CPG), developing innovative strategies, new products, and leading business organizations. Prior to Joining Agilent, Blandine founded and grew Bio2Market, a consulting firm focused on supporting companies at the intersection of Machine Learning and Life Sciences with go-to-market strategies and commercial execution plans for drug discovery, diagnostic or digital health companies. Before founding Bio2Market, during her time at Guardant Health, Blandine led a cross-functional team to expand the use of their next-generation sequencing test in cancer drug development clinical trials, with over 50 biopharma companies. Following, as VP of Business Development at Freenome, she implemented their business strategy to accelerate a multi-analyte platform powered by machine learning for a cancer, early-detection test.
As targeted therapies have opened up precision medicine approaches to cancer treatment, oncologists and patients are increasingly moving to liquid biopsy as a front-line diagnostic approach to detection of actionable mutations to enable faster treatment decisions. Mutation detection in ctDNA has been shown to highly correlate to tissue biopsy for making treatment decisions, faster results and has the additional advantage of simplified specimen collection. Liquid biopsy represents an emerging paradigm shift in oncology practice and this session will discuss its promise and challenges from the Pharma, biotech and medical affairs perspectives.